TRACON Pharmaceuticals, Inc. (NASDAQ:TCON – Get Free Report) passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.95 and traded as low as $0.11. TRACON Pharmaceuticals shares last traded at $0.11, with a volume of 18,037 shares changing hands.
Analyst Upgrades and Downgrades
A number of equities research analysts recently issued reports on the company. StockNews.com started coverage on TRACON Pharmaceuticals in a research note on Thursday. They issued a “hold” rating on the stock. HC Wainwright reiterated a “neutral” rating on shares of TRACON Pharmaceuticals in a research report on Monday, July 1st.
Get Our Latest Stock Report on TRACON Pharmaceuticals
TRACON Pharmaceuticals Stock Performance
TRACON Pharmaceuticals (NASDAQ:TCON – Get Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.94) earnings per share (EPS) for the quarter. The business had revenue of $0.06 million during the quarter.
TRACON Pharmaceuticals Company Profile
TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.
Read More
- Five stocks we like better than TRACON Pharmaceuticals
- Canadian Penny Stocks: Can They Make You Rich?
- Can Costco Stock Hit New Highs as Interest Rates Drop?
- The How and Why of Investing in Gold Stocks
- These 3 Stocks Show How to Navigate Declining Consumer Confidence
- What Does Downgrade Mean in Investing?
- MicroStrategy’s Returns Are 3X Higher Than Bitcoin: Time to Buy?
Receive News & Ratings for TRACON Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.